A Comprehensive Report for decision making

Drug Developer's Intelligence Report

Oncology Intelligence

2013

This Report is only Available on request...​

Kindly Check the Latest Updated Volume of this Report

RELEASED - JANUARY 2013

624

Oncology Drug Developers

It is an excellent report that has a wide variety of oncology information all in one place.

- Dr. Oleh Denysyk

First Report to Cover all Aspects of Cancer Drug Development Intelligence

largest coverage

providing intelligence at fingertips

1
Countries

Largest Coverage with 31 Countries covered Globally

1
Drug developers

462 Clinical, 161 Preclinical stage Cancer Companies Profiles

1
Molecules

Individual Drug Mechanism of Action & Drug Target

1
Cancer Targets

Emerging Cancer Drug Targets Details

intelligence supercharged

840 pages full of insights

HOW ONCOLOGY INTELLIGENCE- A Comprehensive Report for Decision Making 2013
CAN HELP YOU?

Oncology Intelligence (OI2013) is the most advanced and updated intelligence option available for drug developers. It first time combines the business and scientific intelligence to provide clear actionable intelligence.

OI2013 is a first interactive report which covers vast and largest updated dataset for cancer treatment molecules with individual company’s profiles, holding developmental / marketing rights to these molecules. It also contains oncology focused deals, funding options and technology platforms, established vs. emerging cancer drug targets with complete details and role in cancer, Top companies research strategies, their drift towards cancer indications, market forecast of all major cancer indications with drugs competitive position and much more.

Crystal Clear Intelligence…… Intelligence to Decide & Act……

For more details visit www.omicsx.com/reports.html

OI 2013 COVERS:

COMPLETE CANCER CLINICAL PIPELINE (PHI/PHII/PHIII) & LATE PRECLINICAL PIPELINE.
DESCRIPTION OF DRUG TECHNOLOGIES, DRUGS IN DEVELOPMENT WITH TARGETS & CLINICAL TRIAL STATUS.
19 CANCER INDICATIONS (full coverage with market forecast)
TOP 10 COMPANIES DRUG DEVELOPMENT STRATEGIES
1650+ CANCER DRUGS IN DEVELOPMENT
850+ ONCOLOGY FOCUSED DEALS
624 CANCER COMPANIES PROFILES
210+ CANCER DRUG TARGETS
170+ ORPHAN DRUG STATUS
2012 CORPORATE ACTIONS & CLINICAL DRUG DEVELOPMENT UPDATES

Major Advantages with Report:

1st Interactive Report which provides complete picture on oncology drug discovery.

1st Report which clearly de-marks what Top companies development strategies are across cancer drug targets and all cancer
indications with business deals and acquisitions.

1st Report with info graphics representations which can be used in ppts. to make effective presentations.

1st Interactive Report which acts as an complete source book to provide comprehensive picture on cancer drug discovery by eliminating non focused information and is must for any professional linked with oncology rug discovery to keep himself/herself updated in drug discovery.

1st Report where each and every data is validated, and one can check all by effective cross linking within e-copy and outside with valid URL link.

1st Report which is crafted by Team of Scientists and Professionals working on Cancer with inputs directly from Cancer Drug Companies, where ever it was required.

1st Report which is very economically priced, with such amount of data; and is only possible due to direct marketing.

Foreword
List of Figures
List of Tables
List of Boxes
List of Companies (Clinical & Late Pre-clinical Stage)
Executive Summary

Section A : Oncology Clinical Pipeline Companies – Infographics
Worldwide Distribution of Cancer Clinical Pipeline Companies (457 Companies)
Global division of cancer clinical pipeline companies;
Distribution of cancer clinical companies in Eurasia Region;
Diverse vs. Exclusive cancer research focus companies.
Division of Oncology Clinical Pipeline Companies on the Basis of Ownership
Distribution and number of Public, Private and Subsidiary companies;
Country wise (Europe and Asia) ownership division;
Market Capitalization distribution of oncology clinical pipeline companies.
Division of Oncology Clinical Companies on the Basis of Market Valuation
Cancer clinical companies on the basis of assets valuation;
Geographic distribution of Large, Mid and Small size companies;
Comparative study between ownership and valuation for cancer clinical companies.
Division of Oncology Clinical Pipeline Companies on the Basis of Founded Year
Past 21 years Company Incorporation pattern of cancer clinical companies.
Division of Oncology Clinical Pipeline Companies on the Basis of Human Resource
Human Resource distribution patters in cancer clinical development companies;
Top 10 cancer drug development companies (in terms of employee numbers).
Oncology Companies Profiles – United States of America
State wise distribution of companies;
Cancer Innovation supporting states of USA.

Section B : Profile of Oncology Drugs in Clinical Development – Infographics

Distribution of Oncology Molecules in Clinical Development (1037 molecules)
Total number of Small, Biologics and Non Biological complex molecules in clinical development.
Total number of cancer molecules in development in USA, Europe, Asia and Rest of the World.
Molecule development strategies – Top 10 companies vs. remaining 447 companies.
Top 20 Oncology Drug Development Companies (In terms of molecules in Clinical Development)
Top 20 Cancer clinical development companies, their molecule types (small, biologics & NBCM), clinical phases and Indications.
Monoclonal Antibodies in Clinical Development (171 molecules)
Monoclonal antibodies in clinical development with developer and partner name, antibody target, isotype and drug development indications.
Cancer Vaccines in Clinical Development (102 molecules)
Cancer Vaccines in clinical development with short description, developer and partner name, drug target and development Indications.
Cancer Targeting Antibodies Drug Conjugates in Clinical Development (43 molecules) ADCs in clinical development, with short description of antibody and toxin attached; developer and partner name; its target and development Indications.
Cancer Targeting Recombinant Protein Therapies in Clinical Development (39 molecules) Recombinant/Fusion Protein in clinical development with short description, developer and partner
name, their targets and development Indications.
Cancer Targeting Synthetic Peptides in Clinical Development (14 molecules)
Synthetic peptides/proteins in clinical development with short description, developer and partner name, their targets and development Indications.
Cancer Targeting Gene Therapies in Clinical Development (11 molecules)
Gene Therapies and plasmid DNA based therapies clinical development with short description, its developer and partner name; drug target and development Indications.
Oncolytic Virus Based Therapies in Clinical Development (22 molecules)
Oncolytic virus based Therapies in Clinical Development clinical development with short description, its developer and partner name; drug target and development Indications.
Cell Based Therapies for cancer treatment in Clinical Development – Stem Cells/T-Cells & Miscellaneous other cell based therapies clinical development with short description, its developer and partner name; drug target and development Indications.
Other Biological Therapies in Clinical Development (22 molecules)
Remaining biological therapies in clinical development for cancer treatment, with short description, their developer and partner name; drug target and development Indications.
Protein KinasesAn Emerging Class of Cancer Drug Targets
Protein kinases vs other cancer drug targets in clinical development;
Comparative developmental profile of protein kinases, with molecules and indications numbers.
Top four kinases classes targeting cancer with their molecule numbers;
Cancer targeting kinases development strategies – Top 10 companies vs. remaining 447 companies.
Established kinases in cancer drug discovery, their FDA approval years;Annual sales and indications.
Anticipated protein kinases launch In 2013, with cancer indications.

Complete List of Cancer Drug Targets in Clinical Development (227 Targets)
Protein Kinases as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(47 Targets with 874 molecules in development)
Tumor Nacrosis Factors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(12 Targets with 36 molecules in development)
G-coupled Receptors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(8 Targets with 24 molecules in development)
Tumor Surface Antigens as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(8 Targets with 24 molecules in development)
Trancsription Factors as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(8 Targets with 24 molecules in development)
Targeting Cellular Metabolites as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.
(8 Targets with 24 molecules in development)
Growth Factor as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development.
(8 Targets with 24 molecules in development)
Miscellaneous Other Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location
& Functions, Short Description with drugs in clinical development. (8 Targets with 24 molecules in development)

Section C : Profile of Oncology Indications in Clinical Development- Infographics

Distribution of Oncology Indications in Clinical Development (2656 indications)
Division of 2656 indications for 1037 Molecules, in drugs types – Small, Biologic and NBCM.
Top 7 Cancers in terms of highest numbers of molecules in clinical development.
Geographic distribution of Clinical Indications and its correlation with number of molecules from similar region in development; Phase-Wise Breakup of total Indications;
Cancer Clinical Indications strategies – Top 10 companies vs. remaining 447 companies; Comparative analysis on the preference of Top 10 companies for Small Molecule Vs. Biologics, in compare to remaining 447 companies.
Top 10 Companies Vs Remaining 447 Companies
A competitive intelligence demarking the preference of Large Pharma majors to Small Innovators – their choice of targets; cancer indications; clinical phases and valuations (market capitalization).
Clinical Development Profile – Lung Cancer – Epidemiology ; Current Market Size & Forecast ; Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Lung Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Lung Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).

Clinical Development Profile-Breast Cancer– Epidemiology ; Current Market Size & Forecast ; Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Breast Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Breast Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Colorectral Cancer – Epidemiology ; Current Market Size & Forecast ; Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Colorectral Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Colorectral Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Malenoma Cancer – Epidemiology ; Current Market Size & Forecast ;Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Melenoma Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Melenoma Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Prostate Cancer – Epidemiology ; Current Market Size & Forecast ;Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Prostate Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Prostate Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Ovarian Cancer – Epidemiology ; Current Market Size & Forecast ;Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Ovarian Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution;
Drug Top 10 companies Vs others; Protein Kinases in Development for Ovarian Cancer Treatment;Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Pancreatic Cancer – Epidemiology ; Current Market Size & Forecast ;Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast; Ph III Molecules -Key Partners & & Expected Launch; Strong Pipeline Companies; Total No. of Cancer Cure Molecules in Development Vs. Pancreatic Cancer Molecules – their division as Small, Biologics & NBCM; Clinical Phase-wise and partnering molecules distribution; Total No. of Companies Vs. Lung Cancer Drug Developers; their geographic distribution; Drug Top 10 companies Vs others; Protein Kinases in Development for Pancreatic Cancer Treatment; Monoclonal Antibodies, Vaccines and other Biologics in clinical development, Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile-Hepatocellular Carcinoma -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Gastric Cancer – Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Multiple Myeloma -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Leukemia – Epidemiology, Current Market Size & Forecast ; Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Non Hodgkin Lymphoma -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Hodgkin Lymphoma -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Brain Cancer – Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Head & Neck Cancer – Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Renal Cell Carcinoma -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Bladder Cancer -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Clinical Development Profile – Thyroid Cancer -Epidemiology, Current Market Size & Forecast; Ph III Molecules-Key Partners & expected Launch; Ph II & Ph I Clinical Pipeline (including partners).
Orphan Drug in Clinical Development for Cancer Treatment (145 Molecules / 174 Orphan Indications)
Name of Drug and Developer, current clinical phase of development, its Orphan drug Indications and orphan status providing agencies – USFDA and EMEA.
Onocology Clinical PipelineNew Entrants 2012 – Name of Drug and Developer, month of entry of the molecule, clinical trial no., and indications.
Onocology Clinical PipelineMajor Failures 2012 – Name of Drug and Developer, month of exit of the molecule, clinical trial no., and indications.
Onocology Clinical PipelineMajor Advances 2012 – Name of Drug and Developer, month of entry of the molecule, clinical trial no., indications and descripition.

Section D : Oncology Corporate Management Actions – 2012

US FDA New Drugs Approvals – 2012 (14 Drug Approvals)
US FDA Approved Drugs’ Brand & Established names, Approval Month, Developer & Marketing Partners and Indications.
Oncology Focused Mergers & Acquistions – 2012 (18 Deals)
Oncology focused Mergers and Acquisitions, Month of Transition, Deal type & Size, Principal Focus/Description.
Oncology Focused Partnering & Collaborations – 2012 (71 Deals)
Licenser/Licensee Details, Month of Transition, Deal Size, Upfront / Milestones payments, Principal Focus/Description.
Oncology Assets Acquisition – 2012 (18 Deals)
Oncology Drug/Assets Acquirer & Seller, Month of Transition, Deal Size, Upfront/Milestones payments, Short Description.
Oncology Assets Termination – 2012 (06 Deals)
Partnering Assets, Partners, Month of Transition, End outcome, Short Description.
Oncology Company / Academic Partnerships – 2012 (26 Deals)
Academia/Non-profit and Company names, Month of Transition, Main Objectives of the Collaboration.
Grants Awarded to Oncology Drug Development Companies – 2012 (41 Grants)
Funding Agency and Company name, Month of Transition, Grant Value and Principal Focus, Objectives of the Collaboration.
Oncology Drug Discovery Focused Venture Financing – 2012 (57 Deals)
Company Name, Fund Raised, Financing Round, Month of Transition, Key Investors.
Key Management (CXOs/Presidents) Appointments in Oncology Drug Discovery Companies – 2012 (132 Appointments)
Company Name, Month of Appointment, Name, Position, Description.

Section E : Individual Oncology Company Profile (with active Clinical Pipeline)
A to Z Alphabetical Profiles of Cancer Clinical Drug Development Companies (457 Companies)
Individual company Page/s includes: Management Profile –Address, Contact phone number, e-mail, employees number range, key management people name (CXOs) and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 16th Dec. 2012).
Company Profile – Key technology platform, Oncology centered deals, collaborations and business insights, key investors and key partners.
Clinical Pipeline Profile – Drug name, its targets with details, various development indications for cancer cure with current clinical trials and trials status (Active, Requiting, Completed etc), FDA/EMEA Orphan drug status, Special Protocol Assessment , fast track approvals etc; company’s preclinical pipeline.

Section F : Individual Oncology Company Profile (with active Preclinical Pipeline)
☐ Exclusive & Emerging Oncology Preclinical Drug Development Companies – Infographics
Worldwide exclusive preclinical cancer drug discovery companies; Emerging trends in cancer drug discovery; Exclusive pre-clinical drug development assets vs. cancer clinical companies’ preclinical assets; Distribution of exclusive cancer preclinical companies in United States America and Euro-Asia Region.
A to Z Alphabetical Profiles of Cancer Pre-Clinical Drug Development Companies (136 Companies)
Individual company Page/s includes: Management Profile – Address, Contact phone number, e-mail, employees number range, key management people name (CXOs) and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 16th Dec. 2012).
Company Profile – Key technology platform, Oncology centered deals, collaborations and business insights, key investors and key partners.
Clinical Pipeline Profile – Drug name, its targets with details, various development indications for cancer cure, drug discovery/Lead Optimization pipeline.

Appendix A: List of Molecules in Clinical Development for Cancer Cure

Appendix B: Country wise Oncology Companies – List

List of Abbrevations

Figure A.1 Global distribution of cancer clinical pipeline companies (457 Cancer Clinical Companies).
Figure A.2 Distribution of cancer clinical pipeline companies in Euro-Asia Region.
Figure A.3 Diverse vs. Exclusive cancer clinical drug development companies.
Figure A.4 Worldwide division of companies on the basis of Ownership (Public, Private & Subisidary).
Figure A.5 Country-wise distribution of cancer clinical pipeline companies on the basis of Ownership.
Figure A.6 Comparison of Market Capitalization of listed companies (with active cancer clinical pipeline) of USA, Europe & ROW.
Figure A.7 Division of cancer clinical companies on the basis of Assets Valuations (Large, Mid & Small).
Figure A.8 Geographic distribution of Large, Mid and Small size companies.
Figure A.9 Comparative study of cancer clinical companies on the basis of Assets Valuation & Ownership.
Figure A.10 Distribution of cancer clinical companies on the basis of year of Incorporation/formation.
Figure A.11 Bar Graph showing yearwise incorporation of cancer clinical companies form 1991 onwards, (with subdividion of graph for Large, Mid and Small size companies formation years).
Figure A.12 Division of 457 cancer clinical companies on the basis of Human Resource employed.
Figure A.13 A. Distribution of cancer clinical companies within different States of U.S.A, to identify cancer research clusters.
                      B. Top Five U.S.A States,with highest number of cancer clinical companies.
Figure A.14 Comparison between California State companies to remaining cancer clinical companies of U.S.A on the basis of Ownership and Market Valuation.

 

Figure B.1 Distribution of Oncology Cure Molecules in Clinical Development (1037 Molecules).
A. Division of total number of molecules in Small, Biologics & Non Biologics Complex Molecules.
B. Further division of Biologics into Monoclonal Antibodies, Vaccines, Antibody Drug Conjugates,
Figure B.2 Recombinant Proteins, Oncolytics Virus Based drugs, Gene Therapies and other biologics.
Distribution of total cancer molecules in development in U.S.A, Europe, Asia & Rest of the World.

Figure B.3 Molecule development strategies:-
A. Total molecules in development – Top 10 companies vs. remaining 447 companies.
B. Top 10 companies – Small Molecules vs. Biologics.
C. Remaining 447 companies – Small Molecules vs. Biologics.

Figure B.4 Clinical phase-wise (Ph I/PhII/PhIII) distribution of 1037 molecules.

Figure B.5 A. Phase-wise distribution of Small Molecules in clinical development for cancer cure.
B. Top 10 companies Small Molecules developing strategies.
C. Remaining 447 companies Small Molecules developing strategies.

Figure B.6 A. Phase-wise distribution of Biologics in clinical development for cancer treatment.
B. Top 10 companies Biologics developing strategies.
C. Remaining 447 companies Biologics developing strategies.

Figure B.7 Clinical phase-wise division of cancer molecules in development in U.S.A, Europe, Asia & RoW.

Figure B.8 Protein Kinase in cancer drug development
A. Total number of Indications – Protein Kinases vs. others.
B. Total number of Molecules – Protein Kinases vs. others.
C. Clinical phase-wise distribution of Protein Kinases in cancer drug development.

Figure B.9 A. Distribution of total Kinases in cancer clinical development in U.S.A, Europe, Asia & RoW.
B. Division of Kinase as Small, Biologics & Non-Biologics Complex Molecules (NBCM).

Figure B.10 Top four Protein Kinases in cancer clinical drug development (w.r.t molecules in development).
Figure B.11 Top three cancer Indications with highest numbers of Protein Kinases in clinical development.
Figure B.12 Protein Kinases Molecules development Strategies:-
A. Total Kinases in development – Top 10 companies vs remaining 447 companies.
B. Top 10 companies – clinical phase-wise distribution of Protein Kinases.
C. Remaining 447 companies – clinical phase wise distribution of Protein Kinases.

Table A.1  Top 10 Cancer drug development companies (in terms of employee number).

Table B.1  Top 20 companies with highest number of cancer clinical molecules in development.

Table B.2  Cancer molecules and clinical indications between Small, Mid and Large size companies.
Table B.3 Worldwise percentage distribution of companies and molecules on the basis of Valuations.
Table B.4 Monoclonal Antibodies in clinical development (171 Molecules-developer, partner, target, isotypes & indications).
Table B.5 Cancer Vaccines in clinical development (102 vaccines-developer, partner, target, indications & comments).
Table B.6 Antibody Drug Conjugates in clinical development (43 Molecules-developer, partner, target, indications, comments).
Table B.7 Fusion Proteins based therapies in clinical trials (39 Molecules-developer, partner, target, indications, comments).
Table B.8 Synthetic Peptides based therapies in clinical trials (14 Molecules-developer, partner, target, indications, comments).
Table B.9 Gene Therapies in clinical development (14 Molecules-developer, partner, target, indications, comments).
Table B.10 PlasmidDNA based therapies in clinical development (5 Molecules-developer, partner, target, isotypes & indications).
Table B.11 Oncolytic Virus based therapies in clinical trials (13 Molecules-developer, partner, target, indications, comments).
Table B.12 T cell based therapies in clinical trials (9 Molecules-developer, partner, target, indications, comments).
Table B.13 Stem cell based therapies in clinical trials (5 Molecules-developer, partner, target, indications, comments).
Table B.14 Other cell based therapies in clinical trials (3 Molecules-developer, partner, target, indications, comments).
Table B.15 Miscellaneous other Biologics in clinical trials (22 Molecules-developer, partner, target, indications, comments).
Table B.16 Approved Kinase Inhibitors for cancer cure (Developer, type, target, approved since, 2012 sales, indications).
Table B.17 Expected new Kinases launch in 2013 (Drug, developer, type, target, expected launch, NCT number, indication).
Table B.18 Cancer Drug Targets – Protein Kinases (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target description).
Table B.19 Cancer Drug Targets – Tumor Nacrosis Factor Family (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.20 Cancer Drug Targets – G-coupled Protein Receptors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.21 Cancer Drug Targets – Tumor Antigens (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.22 Cancer Drug Targets – Transcription Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.23 Cancer Drug Targets – Metabolic Enzymes (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.24 Cancer Drug Targets – Growth Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).
Table B.25 Cancer Drug Targets – Miscellaneous other Targets (individual target name, Gene, protein family, Drugs in development for the target, target Description).

Table C.1 Molecule Development Strategies – Top 10 companies Vs. Remaining 447 companies

(Comparison between total molecules, clinical phases, types, top 7 targets, top 9 indications and market capitalization).

Table C.2 Top selling chemotherapies for Lung Cancer.

Table C.3 Top selling targeted therapies for Lung Cancer.

Table C.4 Molecules in Ph III clinical trials for NSCLC (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.5 Monoclonal Antibodies in various drug development stages for the treatment of Lung Cancer.

Table C.6 Vaccines in various drug development stages for the treatment of Lung Cancer.

Table C.7 Miscellaneous other Biologics in various drug development stages for the treatment of Lung Cancer.

Table C.8 Non Small Lung Cancer (NSCLC) PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.9 Molecules in Ph III clinical trials for Lung Cancer (SCLC) (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.10 Small Cell Lung Cancer (SCLC) PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.11 Top selling Chemotherapies/Hormonal Therapies for Breast Cancer.

Table C.12 Top selling Targeted Therapies for Breast Cancer.

Table C.13 Molecules in Ph III clinical trials for Breast Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.14 Monoclonal Antibodies in various drug development stages for the treatment of Breast Cancer.

Table C.15 Vaccines in various drug development stages for the treatment of Breast Cancer.

Table C.16 Miscellaneous other Biologics in various drug development stages for the treatment of Breast Cancer.

Table C.17 Breast Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.18 Top selling chemotherapies for Colorectal Cancer.

Table C.19 Top selling targeted therapies for Colorectal Cancer.

Table C.20 Molecules in Ph III clinical trials for Colorectal Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.21 Monoclonal Antibodies in various drug development stages for the treatment of Colorectal Cancer.

Table C.22 Vaccines in various drug development stages for the treatment of Colorectal Cancer.

Table C.23 Miscellaneous other Biologics in drug development stages for the treatment of Colorectal Cancer.

Table C.24 Colorectal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.25 Top selling chemotherapies for Melanoma Cancer.

Table C.26 Top selling targeted therapies for Melanoma Cancer.

Table C.27 Molecules in Ph III clinical trials for Melanoma Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.28 Monoclonal Antibodies in various drug development stages for the treatment of Melanoma Cancer.

Table C.29 Vaccines in various drug development stages for the treatment of Melanoma Cancer.

Table C.30 Miscellaneous other Biologics in drug development stages for the treatment of Melanoma Cancer.

Table C.31 Melanoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.32 Other Skin Cancers Including Non-Melanoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.33 Top selling Chemotherapies for Prostate Cancer.

Table C.34 Top selling Targeted therapies for Prostate Cancer.

Table C.35 Molecules in Ph III clinical trials for Prostate Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.36 Monoclonal Antibodies in various drug development stages for the treatment of Prostate Cancer.

Table C.37 Vaccines in various drug development stages for the treatment of Prostate Cancer.

Table C.38 Miscellaneous other Biologics in drug development stages for the treatment of Prostate Cancer.

Table C.39 Prostate Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.40 Top selling chemotherapies for Ovarian Cancer.

Table C.41 Molecules in Ph III clinical trials for Ovarian Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.42 Monoclonal Antibodies in various drug development stages for the treatment of Ovarian Cancer.

Table C.43 Vaccines in various drug development stages for the treatment of Ovarian Cancer.

Table C.44 Miscellaneous other Biologics in drug development stages for the treatment of Ovarian Cancer.

Table C.45 Ovarian Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.46 Cervical Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.47 Fallopian Tube Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.48 Peritoneal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.49 Endometrial Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.50 Top selling chemotherapies for Pancreatic Cancer.

Table C.51 Top selling targeted therapies for Pancreatic Cancer.

Table C.52 Molecules in Ph III clinical trials for Pancreatic Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.53 Monoclonal Antibodies in various drug development stages for the treatment of Pancreatic Cancer.

Table C.54 Vaccines in various drug development stages for the treatment of Pancreatic Cancer.

Table C.55 Miscellaneous other Biologics in drug development stages for the treatment of Pancreatic Cancer.

Table C.56 Pancreatic Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.57 Neuroendocrine Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.58 Esophageal Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.59 GastroIntestinal Stromal Tumor Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.60 Biliary Tract Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.61 Gall Bladder Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.62 Midgut Carcinoid Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.63 Cholangiocarcinoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.64 Anal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.65 Top selling targeted therapies for Hepatocellular Carcinoma.

Table C.66 Molecules in Ph III clinical trials for Hepatocellular Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.67 Hepatocellular Carcinoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.68 Top selling targeted therapies for Gastric Cancer.

Table C.69 Molecules in Ph III clinical trials for Gastric Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.70 Gastric Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.71 Molecules in Ph III clinical trials for Multiple Myeloma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.72 Multiple Myeloma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.73 Top selling targeted therapies for Leukemia.

Table C.74 Molecules in Ph III clinical trials for Leukemia (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.75 Acute Myeloid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.76 Acute Myelogenous Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.77 Acute Lymphoid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.78 Acute Lymphocytic Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.79 Chronic Myeloid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.80 Chronic Myelogenous Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.81 Chronic Myelomonocytic Leukemia PipelineClinical stage drugs, developers, partners & targets.

Table C.82 Chronic Lymphoid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.83 Top selling targeted therapies for Non Hodgkin Lymphoma.

Table C.84 Molecules in Ph III clinical trials for Non Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.85 Non Hodgkin Lymphoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.86 Waldenstrom’s MacroglobulinemiaClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.87 Molecules in Ph III clinical trials for Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.88 Hodgkin Lymphoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.89 Molecules in Ph III clinical trials for Brain Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.90 Glioblastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.91 Neuroblastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.92 Medullolastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.93 Anaplastic Astrocytoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.94 Top selling targeted therapies for Head & Neck Cancer.

Table C.95 Molecules in Ph III clinical trials for Head & Neck Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.96 Head & Neck Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.97 Nasopharynx Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.98 Oral Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.99 Top selling targeted therapies for Renal Cell Carcinoma.

Table C.100 Molecules in Ph III clinical trials for Renal Cell Carcinoma (Drug, developer, partner, indications,  combination drugs in trial, line of therapy, target, expected launch).

Table C.101 Renal Cell Carcinoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.102 Wilm’s Tumor PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.103 Top selling targeted therapies for Bladder Cancer.

Table C.104 Molecules in Ph III clinical trials for Bladder Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.105 Bladder Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.106 Top selling targeted therapies for Thyroid Cancer.

Table C.107 Molecules in Ph III clinical trials for Thyroid Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.108 Thyroid Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.109 Molecules in Ph III clinical trials for Sarcoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.110 Sarcoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets).

Table C.111 Other Rare Cancer Indications Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.112 Orphan Drug Status cancer molecules in clinical development (145 Molecules with 174 orphan indications)

(Drug Name, Phase, Orphan indication, developer, USFDA/EMEA approvals).

Table C.113 US FDA New Oncology Drug Approvals -2012 (Developer, month of approval, partner, drug proprietary name, established name, approved indications with disease state)

Table C.114 Oncology Clinical Pipeline- Major Drug Failures 2012 (Drug, Developer, month, phase, indications, comments).

Box C.1 Lung Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.2 Strong Clinical Pipeline Companies – Lung Cancer.

Box C.3 Breast Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.4 Strong Clinical Pipeline Companies – Breast Cancer.

Box C.5 Colorectal Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.6 Strong Clinical Pipeline Companies – Colorectal Cancer.

Box C.7 Melanoma Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.8 Strong Clinical Pipeline Companies – Melanoma Cancer.

Box C.9 Prostate Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.10 Strong Clinical Pipeline Companies – Prostate Cancer.

Box C.11 Ovarian Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.12 Strong Clinical Pipeline Companies – Ovarian Cancer.

Box C.13 Other Gynecologic Malignancies Indications.

Box C.14 Pancreatic Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.15 Strong Clinical Pipeline Companies – Pancreatic Cancer.

Box C.16 Other Gastrointestinal Indications.

Box C.17 Hepatocellular Carcinoma-An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.18 Gastric Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.19 Multiple Myeloma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.20 Leukemia- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.21 NonHodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.22 Hodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.23 Brain Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.24 Head & Neck Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.25 Renal Cell Carcinoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.26 Bladder Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.27 Thyroid Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.28 Sarcoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Other Reports in this series

For Purchase, Kindly check the latest report available in this series...

Oncology Intelligence 2013
Comprehensive Decision Making Intelligence derived from Active 624 Oncology Drug Developers.
Oncology Intelligence 2014
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
Oncology Intelligence 2017
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
Oncology Intelligence 2020
Upcoming Comprehensive Decision Making Report derived from Active 1250+ Oncology Drug Developers.
January 2013
March 2014
October 2016
Feburary 2020